{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:55:44Z","timestamp":1793156144427,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>B-cell maturation antigen (BCMA) plays a critical role in regulating B-cell proliferation and survival. There is evidence for BCMA expression in various hematologic malignancies, suggesting that BCMA may play an important role as a biomarker or therapeutic target in these diseases. Given advances in understanding the role of BCMA in B-cell development and the promise of BCMA as a therapeutic target, a systematic review is needed to rigorously assess the evidence for BCMA expression and identify areas of consensus and future research. The objective of this review was to summarize the evidence on BCMA protein and mRNA expression across hematologic malignancies. Using a PubMed database search up to 28 August 2019, a systematic literature review of publications reporting BCMA expression in patients with hematologic malignancies was conducted. Data from published congress abstracts presented at the American Society of Clinical Oncology and the American Society of Hematology were also searched. Studies that assessed BCMA expression (protein or mRNA) in patients of any age with hematologic malignancies were included. A total of 21 studies met inclusion criteria and were included in the review. BCMA was expressed in several hematologic malignancies, including multiple myeloma (MM), chronic lymphocytic leukemia, acute B-lymphoblastic leukemia, non-Hodgkin lymphoma (NHL), and Hodgkin lymphoma. BCMA was expressed at uniformly high levels across all 13 MM studies and at low to moderate levels in acute myeloid leukemia and acute lymphoblastic leukemia. These results suggest that BCMA is a relevant target in MM as well as in a subset of B-cell leukemia. BCMA expression in Hodgkin lymphoma and NHL varied across studies, and further research is needed to determine the utility of BCMA as an antibody target and biomarker in these diseases. Differences in sample type, timing of sample collection, and laboratory technique used may have affected the reporting of BCMA levels.<\/jats:p>","DOI":"10.1038\/s41408-020-0337-y","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T15:03:56Z","timestamp":1593529436000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["B-cell maturation antigen expression across hematologic cancers: a systematic literature review"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6576-5256","authenticated-orcid":false,"given":"Ahmet","family":"Dogan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyet","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Belani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6485-4839","authenticated-orcid":false,"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,30]]},"reference":[{"key":"337_CR1","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2217\/imt.15.77","volume":"7","author":"YT Tai","year":"2015","unstructured":"Tai, Y. T. & Anderson, K. C. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy 7, 1187\u20131199 (2015).","journal-title":"Immunotherapy"},{"key":"337_CR2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","volume":"199","author":"BP O\u2019Connor","year":"2004","unstructured":"O\u2019Connor, B. P. et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 199, 91\u201398 (2004).","journal-title":"J. Exp. Med."},{"key":"337_CR3","volume":"6","author":"SA Laurent","year":"2015","unstructured":"Laurent, S. A. et al. \u03b3-secretase directly sheds the survival receptor BCMA from plasma cells. Nat. Commun. 6, 7333 (2015).","journal-title":"Nat. Commun."},{"key":"337_CR4","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","volume":"9","author":"SF Cho","year":"2018","unstructured":"Cho, S. F., Anderson, K. C. & Tai, Y. T. Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. Front. Immunol. 9, 1821 (2018).","journal-title":"Front. Immunol."},{"key":"337_CR5","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","volume":"38","author":"MS Topp","year":"2020","unstructured":"Topp, M. S. et al. Anti-B-cell maturation antigen BiTE molecule AMG 420 induces response in multiple myeloma. J. Clin. Oncol. 38, 775\u2013783 (2020).","journal-title":"J. Clin. Oncol."},{"key":"337_CR6","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","volume":"34","author":"N Shah","year":"2020","unstructured":"Shah, N. et al. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia 34, 985\u20131005 (2020).","journal-title":"Leukemia"},{"key":"337_CR7","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","volume":"129","author":"AD Cohen","year":"2019","unstructured":"Cohen, A. D. et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J. Clin. Invest. 129, 2210\u20132221 (2019).","journal-title":"J. Clin. Invest."},{"key":"337_CR8","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","volume":"36","author":"JN Brudno","year":"2018","unstructured":"Brudno, J. N. et al. T cells genetically modified to express an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J. Clin. Oncol. 36, 2267\u20132280 (2018).","journal-title":"J. Clin. Oncol"},{"key":"337_CR9","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","volume":"19","author":"S Trudel","year":"2018","unstructured":"Trudel, S. et al. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 19, 1641\u20131653 (2018). Blood 2017;130:741.","journal-title":"Lancet Oncol"},{"key":"337_CR10","first-page":"2755","volume":"130","author":"P Khattar","year":"2017","unstructured":"Khattar, P. et al. B-cell maturation antigen is exclusively expressed in a wide range of B-cell and plasma cell neoplasm and in a potential therapeutic target for Bcma directed therapies. Blood 130, 2755 (2017).","journal-title":"Blood"},{"key":"337_CR11","volume":"6","author":"S Maia","year":"2011","unstructured":"Maia, S. et al. Aberrant expression of functional BAFF-system receptors by malignant B-cell precursors impacts leukemia cell survival. PLoS ONE 6, e20787 (2011).","journal-title":"PLoS ONE"},{"key":"337_CR12","doi-asserted-by":"crossref","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","volume":"151","author":"A Liberati","year":"2009","unstructured":"Liberati, A. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern. Med. 151, W65\u2013W94 (2009).","journal-title":"Ann Intern. Med."},{"key":"337_CR13","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","volume":"31","author":"A Seckinger","year":"2017","unstructured":"Seckinger, A. et al. Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment. Cancer Cell 31, 396\u2013410 (2017).","journal-title":"Cancer Cell"},{"key":"337_CR14","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/bjh.14145","volume":"174","author":"L Lee","year":"2016","unstructured":"Lee, L. et al. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. Br. J. Haematol. 174, 911\u2013922 (2016).","journal-title":"Br. J. Haematol"},{"key":"337_CR15","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1182\/blood-2010-01-264424","volume":"117","author":"J Quinn","year":"2011","unstructured":"Quinn, J. et al. APRIL promotes cell-cycle progression in primary multiple myeloma cells: influence of D-type cyclin group and translocation status. Blood 117, 890\u2013901 (2011).","journal-title":"Blood"},{"key":"337_CR16","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","volume":"123","author":"Y-T Tai","year":"2014","unstructured":"Tai, Y.-T. et al. Novel anti\u2013B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood 123, 3128\u20133138 (2014).","journal-title":"Blood"},{"key":"337_CR17","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","volume":"19","author":"RO Carpenter","year":"2013","unstructured":"Carpenter, R. O. et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin. Cancer Res. 19, 2048\u20132060 (2013).","journal-title":"Clin. Cancer Res."},{"key":"337_CR18","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41375-018-0278-7","volume":"33","author":"K Kinneer","year":"2019","unstructured":"Kinneer, K. et al. Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells. Leukemia 33, 766\u2013771 (2019).","journal-title":"Leukemia"},{"key":"337_CR19","first-page":"3198","volume":"8","author":"LM Pilarski","year":"2002","unstructured":"Pilarski, L. M. & Belch, A. R. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34(+) hematopoietic progenitors. Clin. Cancer Res. 8, 3198\u20133204 (2002).","journal-title":"Clin. Cancer Res."},{"key":"337_CR20","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.18632\/oncotarget.1145","volume":"4","author":"R Reghunathan","year":"2013","unstructured":"Reghunathan, R. et al. Clonogenic multiple myeloma cells have shared stemness signature associated with patient survival. Oncotarget 4, 1230\u20131240 (2013).","journal-title":"Oncotarget"},{"key":"337_CR21","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1089\/hum.2018.001","volume":"29","author":"KM Friedman","year":"2018","unstructured":"Friedman, K. M. et al. Effective targeting of multiple B-cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells. Hum. Gene Ther. 29, 585\u2013601 (2018).","journal-title":"Hum. Gene Ther."},{"key":"337_CR22","first-page":"447","volume":"7","author":"K Nilsson","year":"1970","unstructured":"Nilsson, K. et al. Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from IgE myeloma patient. Clin. Exp. Immunol. 7, 447\u2013489. (1970).","journal-title":"Clin. Exp. Immunol"},{"key":"337_CR23","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.3181\/00379727-125-32327","volume":"125","author":"Y Matsuoka","year":"1967","unstructured":"Matsuoka, Y. et al. Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma. Proc. Soc. Exp. Biol. Med. 125, 1246\u20131250 (1967).","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"337_CR24","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.ymthe.2018.06.012","volume":"26","author":"J Bluhm","year":"2018","unstructured":"Bluhm, J. et al. CAR T cells with enhanced sensitivity to B cell maturation antigen for the targeting of B cell non-Hodgkin\u2019s lymphoma and multiple myeloma. Mol. Ther. 26, 1906\u20131920 (2018).","journal-title":"Mol. Ther."},{"key":"337_CR25","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","volume":"158","author":"E Sanchez","year":"2012","unstructured":"Sanchez, E. et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br. J. Haematol. 158, 727\u2013738 (2012).","journal-title":"Br. J. Haematol."},{"key":"337_CR26","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1158\/1078-0432.CCR-15-2224","volume":"22","author":"E Sanchez","year":"2016","unstructured":"Sanchez, E. et al. Soluble B-cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma. Clin. Cancer Res. 22, 3383\u20133397 (2016).","journal-title":"Clin. Cancer Res."},{"key":"337_CR27","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3324\/haematol.2016.150896","volume":"102","author":"M Ghermezi","year":"2017","unstructured":"Ghermezi, M. et al. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica 102, 785\u2013795 (2017).","journal-title":"Haematologica"},{"key":"337_CR28","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1182\/blood-2004-11-4463","volume":"105","author":"R Bellucci","year":"2005","unstructured":"Bellucci, R. et al. Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. Blood 105, 3945\u20133950 (2005).","journal-title":"Blood"},{"key":"337_CR29","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.7150\/jca.15966","volume":"7","author":"L Bolkun","year":"2016","unstructured":"Bolkun, L. et al. Involvement of BAFF and APRIL in resistance to apoptosis of acute myeloid leukemia. J. Cancer 7, 1979\u20131983 (2016).","journal-title":"J. Cancer"},{"key":"337_CR30","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/MPH.0b013e31829f3271","volume":"36","author":"B Sun","year":"2014","unstructured":"Sun, B. et al. Raised expression of APRIL in Chinese children with acute lymphoblastic leukemia and its clinical implications. J. Pediatr. Hematol. Oncol. 36, 276\u2013280 (2014).","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"337_CR31","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1182\/blood-2004-02-0762","volume":"104","author":"AJ Novak","year":"2004","unstructured":"Novak, A. J. et al. Expression of BLyS and ist receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 104, 2247\u20132253 (2004).","journal-title":"Blood"},{"key":"337_CR32","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1182\/blood-2005-09-3552","volume":"107","author":"SF Elsawa","year":"2006","unstructured":"Elsawa, S. F. et al. B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstr\u00f6m macroglobulinemia. Blood 107, 2882\u20132888 (2006).","journal-title":"Blood"},{"key":"337_CR33","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/bjh.12645","volume":"164","author":"G Ferrer","year":"2014","unstructured":"Ferrer, G. et al. B cell activation through CD40 and IL4R ligation modulates the response of chronic lymphocytic leukaemia cells to BAFF and APRIL. Br. J. Haematol. 164, 570\u2013578 (2014).","journal-title":"Br. J. Haematol."},{"key":"337_CR34","doi-asserted-by":"crossref","first-page":"6071","DOI":"10.4049\/jimmunol.1102066","volume":"188","author":"M Cols","year":"2012","unstructured":"Cols, M. et al. Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL and CD40L. J. Immunol. 188, 6071\u20136083 (2012).","journal-title":"J. Immunol."},{"key":"337_CR35","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1182\/blood-2006-04-015958","volume":"109","author":"A Chiu","year":"2007","unstructured":"Chiu, A. et al. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood 109, 729\u2013739 (2007).","journal-title":"Blood"},{"key":"337_CR36","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.leukres.2018.07.015","volume":"71","author":"DA Salem","year":"2018","unstructured":"Salem, D. A. et al. Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in myeloma. Leuk. Res. 71, 106\u2013111 (2018).","journal-title":"Leuk. Res."},{"key":"337_CR37","first-page":"947041","volume":"2012","author":"M Pekmezci","year":"2012","unstructured":"Pekmezci, M. et al. The effect of cold ischemia time and\/or formalin fixation on estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 results in breast carcinoma. Patholog. Res. Int. 2012, 947041 (2012).","journal-title":"Patholog. Res. Int."},{"key":"337_CR38","doi-asserted-by":"crossref","first-page":"537","DOI":"10.5858\/2010-0702-RAIR.1","volume":"135","author":"KB Engel","year":"2011","unstructured":"Engel, K. B. & Moore, H. M. Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue. Arch. Pathol. Lab. Med. 135, 537\u2013543 (2011).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"337_CR39","doi-asserted-by":"crossref","first-page":"883","DOI":"10.15252\/msb.20167144","volume":"12","author":"F Edfors","year":"2016","unstructured":"Edfors, F. et al. Gene-specific correlation of RNA and protein levels in human cells and tissues. Mol. Syst. Biol. 12, 883 (2016).","journal-title":"Mol. Syst. Biol."},{"key":"337_CR40","first-page":"1512","volume":"5","author":"DeSousaR Abreau","year":"2009","unstructured":"Abreau, De. Sousa R. et al. Global signatures of protein and mRNA expression levels. Global signatures of protein and mRNA expression levels. Mol. Biosyst. 5, 1512\u20131526 (2009).","journal-title":"Global signatures of protein and mRNA expression levels. Mol. Biosyst."},{"key":"337_CR41","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood.2019000050","volume":"134","author":"MJ Pont","year":"2019","unstructured":"Pont, M. J. et al. \u03b3-secretase inhibition increases efficacy of BCMA-specific Chimeric Antigen Receptor T Cells in multiple myeloma. Blood 134, 1585\u20131597 (2019).","journal-title":"Blood"},{"issue":"Supplement_1","key":"337_CR42","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1182\/blood-2019-129405","volume":"143","author":"AJ Cowan","year":"2019","unstructured":"Cowan, A. J. et al. Efficacy and safety of fully human Bcma CAR T cells in combination with a gamma secretase inhibitor to increase Bcma surface expression in patients with relapsed or refractory multiple myeloma. Blood 143(Supplement_1), 204 (2019).","journal-title":"Blood"},{"key":"337_CR43","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1182\/blood.V67.6.1542.1542","volume":"67","author":"AF Gazdar","year":"1986","unstructured":"Gazdar, A. F. et al. Establishment and characterization of a human plasma cell myeloma culture having a rearranged cellular myc proto-oncogene. Blood 67, 1542\u20131549 (1986).","journal-title":"Blood"},{"key":"337_CR44","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0301-472X(03)00023-7","volume":"31","author":"S Greenstein","year":"2003","unstructured":"Greenstein, S. et al. Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. Exp. Hematol. 31, 271\u2013282 (2003).","journal-title":"Exp. Hematol"},{"key":"337_CR45","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/ijc.2910290502","volume":"29","author":"A Togawa","year":"1982","unstructured":"Togawa, A. et al. Establishment and characterization of a human myeloma cell line (KMM-1). Int. J. Cancer 29, 495\u2013500 (1982).","journal-title":"Int. J. Cancer"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0337-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0337-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0337-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T14:31:23Z","timestamp":1670250683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0337-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,30]]},"references-count":45,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["337"],"URL":"https:\/\/doi.org\/10.1038\/s41408-020-0337-y","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,30]]},"assertion":[{"value":"23 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.T., A.F., J.F., and R.B. are employees of and own stock in Amgen, Inc, developer of 2 BiTE\u00ae immunotherapies (AMG 420 and AMG 701) and 1 ADC (AMG 224) targeting BCMA. O.L. received grants\/research support from Celgene, Amgen, BMS, and Karyopharm; received grants\/research support, honoraria, and other from Janssen; received grants\/research support and other for Takeda; received honoraria from Celgene, Amgen, and Adaptive Biotech; and received other from Merck. A.D. received honoraria and consulting or advisory role fees from Roche, Corvus Pharmaceuticals, Physicians\u2019 Education Resource, Seattle Genetics, Peerview Institute, Oncology Specialty Group, Pharmacyclics, Celgene, Novartis, Takeda, and EUSAPharma; and research grants from National Cancer Institute and Roche. D.S. received honoraria and consulting or advisory role fees from Celgene, Amgen, Merck, Janssen, BMS, Takeda, and Karyopharm; participated in speakers\u2019 bureaus for Celgene, Amgen, Merck, Janssen, BMS, and Takeda; and received research funding from Celgene.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"73"}}